Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

METHODS OF TREATING KERATIN HYPERPROLIFERATION DISORDERS USING mTOR INHIBITORS

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    December 13, 2018
  • معلومة اضافية
    • Document Number:
      20180353487
    • Appl. No:
      15/845847
    • Application Filed:
      December 18, 2017
    • نبذة مختصرة :
      A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration.
    • Claim:
      1. A method of treating psoriasis in a subject comprising: administering to the subject a therapeutically effective amount of an mTOR inhibitor selected from the group consisting of rapamycin (sirolimus), a rapamycin derivative, a rapamycin prodrug, and combinations thereof.
    • Claim:
      2. The method of claim 1, wherein the rapamycin derivative is a member selected from the group consisting of: temsirolimus, everolimus, and combinations thereof.
    • Claim:
      3. The method of claim 1, wherein the rapamycin prodrug is selected from the group consisting of AP-23573, AP-23481, and combinations thereof.
    • Claim:
      4. The method of claim 1, wherein the mTOR inhibitor is rapamycin.
    • Claim:
      5. The method of claim 1, wherein the mTOR inhibitor is a combination of two or more mTOR inhibitors.
    • Claim:
      6. The method of claim 1, wherein the administration of the mTOR inhibitor is oral.
    • Claim:
      7. The method of claim 6, wherein the mTOR inhibitor is administered in an amount from about 2 mg/day to about 20 mg/day.
    • Claim:
      8. The method of claim 1, wherein the administration of the mTOR inhibitor is topical.
    • Claim:
      9. The method of claim 1, wherein the administration of the mTOR inhibitor is transdermal.
    • Claim:
      10. The method of claim 1, wherein the administration of the mTOR inhibitor is intravenous.
    • Claim:
      11. The method of claim 1, wherein the administration of the mTOR inhibitor is both oral and topical.
    • Claim:
      12. The method of claim 11, wherein the mTOR inhibitor administered orally is the same as the mTOR inhibitor administered topically.
    • Claim:
      13. The method of claim 11, wherein the mTOR inhibitor administered orally is different from the mTOR inhibitor administered topically.
    • Claim:
      14. The method of claim 1, wherein the administration of the mTOR inhibitor is both oral and transdermal.
    • Claim:
      15. The method of claim 14, wherein the mTOR inhibitor administered orally is the same as the mTOR inhibitor administered transdermally.
    • Claim:
      16. The method of claim 14, wherein the mTOR inhibitor administered orally is different from the mTOR inhibitor administered transdermally.
    • Claim:
      17. The method of claim 1, wherein psoriasis results from an overexpression or inappropriate expression of a keratin encoded by a mRNA having a terminal oligopyrimidine (TOP) motif.
    • Current International Class:
      61; 61; 61
    • الرقم المعرف:
      edspap.20180353487